All Relations between Schizophrenia and Amisulpride

Publication Sentence Publish Date Extraction Date Species
Seon-Cheol Park, Bong Ju Lee, Jae Hong Park, Hiroaki Kawasaki, Ajit Avasthi, Sandeep Grover, Andi J Tanra, Shih-Ku Lin, Afzal Javed, Chay Hoon Tan, Norman Sartorius, Naotaka Shinfuku, Yong Chon Par. QT interval prolongation noted in one percent of 2553 Asian patients with schizophrenia: Findings from the REAP-AP survey. The Kaohsiung journal of medical sciences. vol 36. issue 12. 2021-10-07. PMID:32772489. these findings indicate the clinical implications that the uses of amisulpride and clozapine and the occurrences of rigidity and hypercholesterolemia may be potential risk factors for qtc prolongation of schizophrenia patients. 2021-10-07 2023-08-13 Not clear
Shanqing Huang, Lu Li, Zhanzhang Wang, Tao Xiao, Xiaolin Li, Shujing Liu, Ming Zhang, Haoyang Lu, Yuguan Wen, Dewei Shan. Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level. Drug design, development and therapy. vol 15. 2021-09-23. PMID:34548782. modeling and simulation for individualized therapy of amisulpride in chinese patients with schizophrenia: focus on interindividual variability, therapeutic reference range and the laboratory alert level. 2021-09-23 2023-08-13 Not clear
Shanqing Huang, Lu Li, Zhanzhang Wang, Tao Xiao, Xiaolin Li, Shujing Liu, Ming Zhang, Haoyang Lu, Yuguan Wen, Dewei Shan. Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level. Drug design, development and therapy. vol 15. 2021-09-23. PMID:34548782. to explain the high inter-individual variability (iiv) and the frequency of exceeding the therapeutic reference range and the laboratory alert level of amisulpride, a population pharmacokinetic (ppk) model in chinese patients with schizophrenia was built based on therapeutic drug monitoring (tdm) data to guide individualized therapy. 2021-09-23 2023-08-13 Not clear
Dnyandev Gadhave, Shrikant Tupe, Amol Tagalpallewar, Bapi Gorain, Hira Choudhury, Chandrakant Kokar. Nose-to-brain delivery of amisulpride-loaded lipid-based poloxamer-gellan gum nanoemulgel: In vitro and in vivo pharmacological studies. International journal of pharmaceutics. vol 607. 2021-09-22. PMID:34454028. therefore, the present research was aimed to fabricate, optimize and investigate the therapeutic efficacy of amisulpride (ams)-loaded intranasal in situ nanoemulgel (ams-ng) in the treatment of schizophrenia. 2021-09-22 2023-08-13 rat
Lin Li, Lu Li, De-Wei Shang, Yu-Guan Wen, Yu-Ping Nin. A systematic review and combined meta-analysis of concentration of oral amisulpride. British journal of clinical pharmacology. vol 86. issue 4. 2021-07-28. PMID:32090363. amisulpride, a first-line schizophrenia treatment, has shown large interindividual variability in plasma/serum levels, often outside the reference range (100-320 ng/ml). 2021-07-28 2023-08-13 Not clear
Réjane Troudet, Wafa Bel Haj Ali, Delphine Bacq-Daian, Inge Winter van Rossum, Anne Boland-Auge, Christophe Battail, Caroline Barau, Dan Rujescu, Philip McGuire, René S Kahn, Jean-François Deleuze, Marion Leboyer, Stéphane Jamai. Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 10. 2021-06-23. PMID:32450569. as part of the optimisation of treatment and management of schizophrenia in europe (optimise) programme, we conducted an rna-seq analysis on 188 subjects with first episode psychosis, all of whom were subsequently treated with amisulpride for 4 weeks. 2021-06-23 2023-08-13 human
Binbin Chen, Chen Wang, Xiangzhen Xu, Haiyan Lyu, Chunling Ma, Gang Chen. Risk of Prolonged Corrected QT Interval With Amisulpride Therapy for Renal Function Management in Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 40. issue 5. 2021-06-02. PMID:32826486. risk of prolonged corrected qt interval with amisulpride therapy for renal function management in patients with schizophrenia. 2021-06-02 2023-08-13 Not clear
Binbin Chen, Chen Wang, Xiangzhen Xu, Haiyan Lyu, Chunling Ma, Gang Chen. Risk of Prolonged Corrected QT Interval With Amisulpride Therapy for Renal Function Management in Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 40. issue 5. 2021-06-02. PMID:32826486. amisulpride (ami) is a popular antipsychotic drug prescribed for the management of schizophrenia. 2021-06-02 2023-08-13 Not clear
F Markus Leweke, Cathrin Rohleder, Christoph W Gerth, Martin Hellmich, Ralf Pukrop, Dagmar Koeth. Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. Frontiers in pharmacology. vol 12. 2021-05-18. PMID:33995015. cannabidiol and amisulpride improve cognition in acute schizophrenia in an explorative, double-blind, active-controlled, randomized clinical trial. 2021-05-18 2023-08-13 Not clear
Guomin Wang, Bo Zhou, Lifeng Zheng, Yanfei Ni, Anle Pa. Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study. Annals of palliative medicine. vol 9. issue 5. 2021-05-14. PMID:33065798. prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study. 2021-05-14 2023-08-13 Not clear
Guomin Wang, Bo Zhou, Lifeng Zheng, Yanfei Ni, Anle Pa. Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study. Annals of palliative medicine. vol 9. issue 5. 2021-05-14. PMID:33065798. this study is aimed to explore whether the improvement of depression symptoms is a predictive factor for the amelioration of the schizophrenia symptoms by amisulpride treatment. 2021-05-14 2023-08-13 Not clear
Juan de Dios Molina, Javier Quintero, Eduardo García-Laredo, Francisco López-Muñoz, Javier Correas-Lauffer, Eduardo Barbudo, Antonio Ceverino, Carlos Mur, E Garcia-Res. Cognitive Effects of Combined Amisulpride and Quetiapine Treatment in Patients With Refractory Schizophrenia: A Naturalistic, Prospective Study. American journal of therapeutics. vol 27. issue 4. 2021-04-21. PMID:31082829. cognitive effects of combined amisulpride and quetiapine treatment in patients with refractory schizophrenia: a naturalistic, prospective study. 2021-04-21 2023-08-13 Not clear
Wang Zhenhua, Chen Haizhi, Li Jing, Fei Xiaocong, Li Jianhua, Liu Jianjun, Lei Lilei, Jin Haiyin. Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists. 2021-03-23. PMID:33754473. occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride. 2021-03-23 2023-08-13 Not clear
Seung-Gul Kang, Seo-Eun Cho, Kyoung-Sae Na, Chi-Un Pae, Seong-Jin Ch. Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 19. issue 1. 2021-02-28. PMID:33508795. clinical usefulness of amisulpride add-on therapy in schizophrenia patients without treatment response to second-generation antipsychotics. 2021-02-28 2023-08-13 Not clear
Zhan-Miao Yi, Peng Men, Shuli Qu, Chaoyun Li, Xin Yu, Suodi Zha. Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China. Expert review of pharmacoeconomics & outcomes research. vol 20. issue 3. 2021-01-22. PMID:32293194. comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in china. 2021-01-22 2023-08-13 Not clear
Zhan-Miao Yi, Peng Men, Shuli Qu, Chaoyun Li, Xin Yu, Suodi Zha. Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China. Expert review of pharmacoeconomics & outcomes research. vol 20. issue 3. 2021-01-22. PMID:32293194. both amisulpride and olanzapine are leading treatments for schizophrenia in china. 2021-01-22 2023-08-13 Not clear
Zhan-Miao Yi, Peng Men, Shuli Qu, Chaoyun Li, Xin Yu, Suodi Zha. Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China. Expert review of pharmacoeconomics & outcomes research. vol 20. issue 3. 2021-01-22. PMID:32293194. this study aimed to investigate the long-term cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in china. 2021-01-22 2023-08-13 Not clear
Christian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Wolfgang Gaebel, Pablo-Emilio Verde, Henrike Kolbe, Christoph U Correll, Stefan Leucht, Stephan Heres, Michael Kluge, Christian Makiol, Andrea Neff, Christina Lange, Susanne Englisch, Mathias Zink, Berthold Langguth, Timm Poeppl, Dirk Reske, Euphrosyne Gouzoulis-Mayfrank, Gerhard Gründer, Alkomiet Hasan, Anke Brockhaus-Dumke, Markus Jäger, Jessica Baumgärtner, Thomas Wobrock, Joachim Corde. A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. European archives of psychiatry and clinical neuroscience. vol 270. issue 1. 2020-11-06. PMID:31486890. a randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (combine): methods and design. 2020-11-06 2023-08-13 Not clear
Christian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Wolfgang Gaebel, Pablo-Emilio Verde, Henrike Kolbe, Christoph U Correll, Stefan Leucht, Stephan Heres, Michael Kluge, Christian Makiol, Andrea Neff, Christina Lange, Susanne Englisch, Mathias Zink, Berthold Langguth, Timm Poeppl, Dirk Reske, Euphrosyne Gouzoulis-Mayfrank, Gerhard Gründer, Alkomiet Hasan, Anke Brockhaus-Dumke, Markus Jäger, Jessica Baumgärtner, Thomas Wobrock, Joachim Corde. A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. European archives of psychiatry and clinical neuroscience. vol 270. issue 1. 2020-11-06. PMID:31486890. amisulpride and olanzapine have shown promising therapeutic efficacy in meta-analyses in monotherapy for people with schizophrenia. 2020-11-06 2023-08-13 Not clear
Ying Liang, Xin Y. The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study. Neuropsychiatric disease and treatment. vol 13. 2020-10-01. PMID:28461752. the effectiveness and safety of amisulpride in chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the escape study. 2020-10-01 2023-08-13 Not clear